about
β(2) -adrenoceptor agonists: current and future directionNew combinations in the treatment of COPD: rationale for aclidinium-formoterolEmerging therapies for severe asthmaStereoselective activity of 2-(4-amino-3-chloro-5- trifluomethyl-phenyl)-2-tert-butylamino-ethanol hydrochloride to improve the pulmonary function in asthma.Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema.Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD.A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study.Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease.Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulationThe Saudi initiative for asthma - 2012 update: Guidelines for the diagnosis and management of asthma in adults and childrenIndacaterol in chronic obstructive pulmonary disease: an update for clinicians.The Saudi Initiative for Asthma - 2016 update: Guidelines for the diagnosis and management of asthma in adults and children.Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair® versus HandiHaler® in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trialIndacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist.Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.Arformoterol tartrate in the treatment of COPD.Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD.Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease.Third-generation long-acting β₂-adrenoceptor agonists: medicinal chemistry strategies employed in the identification of once-daily inhaled β₂-adrenoceptor agonists.Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma.Can β2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?Indacaterol: a novel long-acting β(2) -agonist.An update on bronchodilators in Phase I and II clinical trials.Phenotyping airways disease: an A to E approach.Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to dateVilanterol trifenatate for the treatment of COPD.Pharmacotherapy for exercise-induced asthma: allowing normal levels of activity and sport.Aclidinium inhibits human lung fibroblast to myofibroblast transition.Role of Proteases in Chronic Obstructive Pulmonary Disease.Efficacy, safety, and tolerability of once-daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7-day, crossover study.Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol.Real time analysis of β(2)-adrenoceptor-mediated signaling kinetics in human primary airway smooth muscle cells reveals both ligand and dose dependent differences.Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.Short-acting anticholinergic bronchodilation does not increase cardiovascular events in smokers with mild to moderate pulmonary obstruction.Indacaterol for the treatment of chronic obstructive pulmonary disease.
P2860
Q24604047-D9ADC591-08AE-42F0-B33B-CE4A2F54B10DQ26765303-5FDCF470-702F-44EC-BED8-1753AA17E66FQ26861260-0AB36037-F1FA-4C00-9DBB-75D06E33A905Q33733512-62CD697F-700A-4283-A99E-8BCC654FB582Q33783760-8DC2060B-33D2-4AC5-B356-B38716B8A843Q33934859-1E5464A6-706B-4425-B5CA-9DA9DE01AB0BQ34903093-2EE49AE8-77A3-43AD-8168-511AD6263C23Q35060604-71E5DB23-8ABD-45EE-A7EC-A704A0FF0C09Q35147196-E7BADAF1-DD7C-46D5-94D7-8F28EEAF8691Q35965128-17474291-A14E-4F49-890B-6E331DF83FE4Q36159232-142C8CEC-1BB9-4005-9B52-509397AD54E2Q36422663-81D86A42-F5DD-4EB1-8CC2-6D40B98F5836Q36443777-3EFD58DF-5B06-4263-AF34-A3BC01682189Q36566081-B7631850-4BCE-41B9-96A8-76923520CCFCQ37446886-91EB34FF-B8B6-4043-A66F-C828DE552A9BQ37487619-B2324C45-D880-4D3E-BE2D-2AC9E5CA250BQ37667100-D72226BE-806C-4046-A338-5EEAB283ABC0Q37734436-87DEC7E5-10C7-4FE0-8E9D-EBC5EA2E4C9CQ37804908-1FFC9E30-D0DA-4B04-8D31-7DF3894E2C90Q37846698-A91FB271-D17F-44D1-A9ED-6CCBE00102C6Q37895710-C01096DA-F24A-4481-9AB5-FEB911A017B2Q37937549-C40ECC26-B2FB-4523-87C7-C1152A48ACC5Q37937552-7FAC248B-9E7E-4E6A-BDAB-F5A7899B9F2EQ37937562-21CE0EA8-01F8-48D8-98D3-3CADE8792D4FQ37951672-0762B5FF-82E5-441E-A952-6F49108BABB1Q38002357-FB86BA93-938E-4BA8-B557-48B0CD7E60B1Q38037123-ADA611C7-84C1-430A-9E65-2DBBD1222386Q38062584-15E0F44C-16FF-4DE0-A6A4-88A1F277FCDFQ38248438-EAE8DE9C-1320-4204-9AAB-947A72093F7DQ38432438-FAE606E1-B2D8-4723-88E7-3A186B2C2654Q38824916-2932E8A2-829F-4339-8CD3-CCDDB9D54E32Q39914397-6C2A86B5-5B9C-48CA-91CB-D0E77C31BCA3Q41252525-94C8C449-48AC-42A8-8188-DD2E9F3313BAQ41333629-159E39F5-1A7C-4A63-8FF8-ABF968FD8445Q42285690-70753599-32E0-4AEB-B52D-42AD69CBA611Q42645176-E284E6EA-1BB8-44C6-8367-82A4D226DB19Q42839797-E177787F-7912-45AF-BB32-31922F44F38CQ43509713-033A4AD5-57F7-421E-AC9E-8551EA6F803DQ45172437-374FC658-A60B-49F6-8BF8-308D631D1D63Q48059168-871F60CE-F8B3-4CFA-84C7-5F2CFD55CC2B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel long-acting bronchodilators for COPD and asthma
@en
Novel long-acting bronchodilators for COPD and asthma.
@nl
type
label
Novel long-acting bronchodilators for COPD and asthma
@en
Novel long-acting bronchodilators for COPD and asthma.
@nl
prefLabel
Novel long-acting bronchodilators for COPD and asthma
@en
Novel long-acting bronchodilators for COPD and asthma.
@nl
P2860
P356
P1476
Novel long-acting bronchodilators for COPD and asthma
@en
P2093
P2860
P304
P356
10.1038/BJP.2008.284
P407
P577
2008-07-07T00:00:00Z